Julio Pascual

Summary

Country: Spain

Publications

  1. ncbi [Chronic migraine: treatment]
    Julio Pascual
    Servicio de Neurologia, Hospital Universitario Central de Asturias, Oviedo, Asturias, Espana
    Rev Neurol 54:S31-8. 2012
  2. ncbi Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
    A Oterino
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    J Headache Pain 12:235-8. 2011
  3. ncbi [Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients]
    J Pascual
    Servicio de Neurologia, Hospital Universitario de Salamanca
    Neurologia 21:188-91. 2006
  4. ncbi [Experience with intranasal zolmitriptan in cluster headache]
    J Pascual
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Santander
    Neurologia 21:131-4. 2006
  5. ncbi Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
    Julio Pascual
    Service of Neurology, University Hospital, Salamanca 39008, Spain
    J Headache Pain 7:27-33. 2006
  6. ncbi A woman with daily headaches
    Julio Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    J Headache Pain 6:91-2. 2005
  7. ncbi Primary cough headache
    Julio Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, 39008 Santander, Spain
    Curr Pain Headache Rep 9:272-6. 2005
  8. ncbi Efficacy and tolerability of almotriptan in postmarketing surveillance studies
    Julio Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    Eur Neurol 53:34-40. 2005
  9. ncbi Testing the combination beta-blocker plus topiramate in refractory migraine
    J Pascual
    Service of Neurology, University Hospital, Salamanca, Spain
    Acta Neurol Scand 115:81-3. 2007
  10. ncbi [Spanish contribution to the clinical development of eletriptan: an analysis of controlled studies]
    J Pascual
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Santander
    Neurologia 19:414-9. 2004

Collaborators

Detail Information

Publications100

  1. ncbi [Chronic migraine: treatment]
    Julio Pascual
    Servicio de Neurologia, Hospital Universitario Central de Asturias, Oviedo, Asturias, Espana
    Rev Neurol 54:S31-8. 2012
    ....
  2. ncbi Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
    A Oterino
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    J Headache Pain 12:235-8. 2011
    ....
  3. ncbi [Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients]
    J Pascual
    Servicio de Neurologia, Hospital Universitario de Salamanca
    Neurologia 21:188-91. 2006
    ..To analyze our experience with the new, 5 mg intranasal formulation of zolmitriptan in the symptomatic treatment of migraine attacks...
  4. ncbi [Experience with intranasal zolmitriptan in cluster headache]
    J Pascual
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Santander
    Neurologia 21:131-4. 2006
    ..The objective is to analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache in daily clinical practice...
  5. ncbi Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
    Julio Pascual
    Service of Neurology, University Hospital, Salamanca 39008, Spain
    J Headache Pain 7:27-33. 2006
    ..In conclusion, PS studies augment our knowledge of antimigraine therapy, giving a more complete picture of how such agents work in the general population...
  6. ncbi A woman with daily headaches
    Julio Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    J Headache Pain 6:91-2. 2005
    ..This experience emphasises that a good clinical interview remains the most important point in the diagnosis and management of headache...
  7. ncbi Primary cough headache
    Julio Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, 39008 Santander, Spain
    Curr Pain Headache Rep 9:272-6. 2005
    ..These clinical characteristics allow its differential diagnosis from other entities, even though a craniocervical magnetic resonance imaging study is mandatory to rule out posterior fossa lesions, especially Chiari type-I malformation...
  8. ncbi Efficacy and tolerability of almotriptan in postmarketing surveillance studies
    Julio Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    Eur Neurol 53:34-40. 2005
    ....
  9. ncbi Testing the combination beta-blocker plus topiramate in refractory migraine
    J Pascual
    Service of Neurology, University Hospital, Salamanca, Spain
    Acta Neurol Scand 115:81-3. 2007
    ..To test treatment combining a beta-blocker plus topiramate in migraine patients previously resistant to the two medications in monotherapy...
  10. ncbi [Spanish contribution to the clinical development of eletriptan: an analysis of controlled studies]
    J Pascual
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Santander
    Neurologia 19:414-9. 2004
    ..Our aim has been to analyze the specific results from the Spanish participation in phase IIIa and IIIb clinical trials vs placebo and compare them with the results obtained in the global clinical development of eletriptan...
  11. ncbi [Influence of botulinum toxin treatment on previous primary headaches in patients with cranio-cervical dystonia]
    J Pascual
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Santander
    Neurologia 19:260-3. 2004
    ..Preliminary data suggest some beneficial effects of botulinum toxin type A (BT-A) on primary headaches...
  12. ncbi How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate
    J Pascual
    Service of Neurology, University Hospital, Paseo de San Vicente 58 132, 37007, Salamanca, Spain
    J Headache Pain 8:90-3. 2007
    ..Our data suggest that the current practice recommending periods of preventive treatment of 3-6 months should be reconsidered for many patients...
  13. ncbi Use of almotriptan in triptan-experienced and triptan-naïve patients
    Julio Pascual
    Service of Neurology, University Hospital, Salamanca, Spain
    Curr Med Res Opin 23:2433-40. 2007
    ..To evaluate the efficacy of oral almotriptan 12.5 mg as an acute treatment for migraine with a focus on triptan-experienced versus triptan-naïve patients...
  14. ncbi Almotriptan: a review of 10 years' clinical experience
    Julio Pascual
    Hospital Universitario Central de Asturias, Oviedo, Spain
    Expert Rev Neurother 10:1505-17. 2010
    ..This suggests that almotriptan is an excellent choice for patients requiring specific acute migraine treatment...
  15. ncbi [Chronic migraine as seen by neurologists and patients: results of the CIEN-mig project (III)]
    Julio Pascual
    Servicios de Neurologia, Hospital Universitario Central de Asturias, Oviedo, Asturias
    Rev Neurol 50:705-10. 2010
    ..Data on the reality of chronic migraine in our clinics are scarce. AIM. To know the frequency of consultation and attitude of the neurologist regarding chronic migraine, and the opinion of patients with this condition...
  16. ncbi [Satisfaction of the migraine patient attending neurology clinics: results of CIEN-mig project (II)]
    Julio Pascual
    Servicios de Neurologia, Hospital Universitario Central de Asturias, 33006 Oviedo, Espana
    Rev Neurol 50:641-5. 2010
    ..Migraine is the most common neurological consultation in our country. AIM. To analyse the satisfaction level of the patient with migraine attending our clinics...
  17. ncbi [Approach of neurologists in Spain to migraine: results of the CIEN-mig project (I)]
    Julio Pascual
    Servicios de Neurologia, Hospital Universitario Central de Asturias, Oviedo, Espana
    Rev Neurol 50:577-83. 2010
    ..Headache is the most frequent neurological reason for consultation in our country...
  18. ncbi [Zonisamide in the preventive treatment of refractory migraine]
    Julio Pascual-Gómez
    Servicios de Neurologia, Hospital Universitario Marques de Valdecilla, Santander, Espana
    Rev Neurol 50:129-32. 2010
    ..Chronic migraine refractory to preventive treatment is a common clinical situation in general neurology clinics. The aim is to analyse our experience with zonisamide in the preventive treatment of patients with frequent refractory migraine...
  19. ncbi [The role of the neuromodulators in the preventive treatment of migraine]
    J Pascual-Gómez
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Cantabria, Espana
    Rev Neurol 49:25-32. 2009
    ..More than one quarter of patients who consult due to migraine need preventive treatment. At least half of these patients do not respond or cannot tolerate classical preventatives: beta-blockers, flunarizine or amitriptyline...
  20. ncbi Other primary headaches
    Julio Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, 39008 Santander, Spain
    Neurol Clin 27:557-71. 2009
    ..Clinicians should be aware that these headaches may be symptomatic to structural lesions and therefore usually require careful neuroimaging evaluation...
  21. ncbi [Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate]
    J Pascual-Gómez
    Servicio de Neurologia, Hospital Universitario de Salamanca, Salamanca, Espana
    Rev Neurol 47:449-51. 2008
    ..About half of the patients with chronic migraine do not respond or do not tolerate the different migraine preventatives...
  22. ncbi Almotriptan in triptan-naïve patients: new evidence of benefits
    J Pascual
    University Hospital of Salamanca, Salamanca, Spain
    Cephalalgia 28:14-20. 2008
    ..These findings indicate that TN patients can expect excellent symptom control when they progress from non-specific analgesia to treatment with almotriptan and support the earlier use of triptans in line with the stratified care paradigm...
  23. ncbi A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine
    Julio Pascual
    Service of Neurology, University Hospital Marqués de Valdecilla UC, Spain
    Expert Opin Pharmacother 5:669-77. 2004
    ..The wafer formulation offers the convenience of being administered without water. As a result of its superior efficacy profile and generally good tolerability, rizatriptan can be considered as a first-line treatment for acute migraine...
  24. ncbi [Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study]
    J Pascual
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Santander, Espana
    Neurologia 18:7-17. 2003
    ..Almotriptan, the most recent drug of the triptan family, has shown good efficacy and tolerability profile in clinical trials...
  25. ncbi [Teaching needs of general practitioners in headaches]
    J Pascual
    Centro Servicio de Neurología, Hospital Universitario Marques de Valdecilla, Santander, Espana
    Neurologia 25:104-7. 2010
    ..Headache in general, and migraine in particular, are the main reasons for general practitioners (GPs) to consult neurology services. Our aim was to analyse the current knowledge of GPs in migraine diagnosis...
  26. ncbi Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients
    J Pascual
    Service of Neurology, Department of Medicine UC, University Hospital Marques de Valdecilla, Santander, Spain
    Cephalalgia 23:961-2. 2003
    ..Controlled trials are now necessary to determine the true advantage in efficacy of this combination in difficult to treat migraineurs...
  27. ncbi Topiramate for patients with refractory migraine: an observational, multicenter study in Spain
    J Pascual
    University Hospital Marqués de Valdecilla UC, Santander
    Neurologia 18:364-7. 2003
    ..The efficacy of current preventive migraine treatments is limited. In addition, tolerability problems are not infrequent...
  28. ncbi Pseudomigraine with lymphocytic pleocytosis
    Julio Pascual
    Service of Neurology, University Hospital Marqués de Valdecilla UC, 39008 Santander, Spain
    Curr Pain Headache Rep 7:224-8. 2003
    ..This autoimmune attack may induce an aseptic leptomeningeal vasculitis, accounting for the headache and the transient symptoms likely through a spreading depression-like mechanism...
  29. ncbi The relationship between homocysteine and genes of folate-related enzymes in migraine patients
    Agustin Oterino
    Department of Neurology, University Hospital Marques de Valdecilla, Santander, Cantabria, Spain
    Headache 50:99-168. 2010
    ..Genetic factors such as the MTHFR C677T polymorphism, and other polymorphisms in folate-related genes associated with high homocysteine levels, may contribute to increasing this vascular risk...
  30. ncbi Multilocus analyses reveal involvement of the ESR1, ESR2, and FSHR genes in migraine
    Agustin Oterino
    University Hospital Marqués de Valdecilla Neurology, Santander, Spain
    Headache 48:1438-50. 2008
    ..Research in this field has been controversial, especially in regard to ESR1 gene findings. None of the reports have yet to approach the problem from a multigenic point of view...
  31. ncbi Association of migraine and ESR1 G325C polymorphism
    Agustin Oterino
    Services of Neurology, Universitary Hospital Marques de Valdecilla, Santander, Spain
    Neuroreport 17:61-4. 2006
    ..Women carrying the C352C genotype were over 3 times more likely to suffer from migraine than those carrying the G325G genotype. Therefore, we conclude that ESR1 G325C polymorphism is associated with migraine in our population...
  32. ncbi LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease
    Jon Infante
    Service of Neurology, University Hospital Marques de Valdecilla, University of Cantabria, 39008 Santander, Spain
    Neurosci Lett 395:224-6. 2006
    ..R1441G was not detected in any of our study subjects. The prevalence of G2019S mutation in unselected late-onset PD patients might be higher than previously reported: 3/16 (18.7%) of familial PD and 5/82 (6.1%) of sporadic PD...
  33. ncbi Antiepileptic drugs for the treatment of chronic and episodic cluster headache: a review
    Julio Pascual
    University Hospital, Salamanca, Spain
    Headache 47:81-9. 2007
    ....
  34. ncbi Family-based association study of chromosome 6p12.2-p21.1 migraine locus
    Agustin Oterino
    University Hospital Marqués de Valdecilla Neurology, Santander, Cantabria, Spain
    Headache 52:393-9. 2012
    ..2-21.1. This locus (named MIGR3) has not been replicated in the only genome-wide association scan study performed to date or in previous genome-wide linkage studies...
  35. ncbi Genetic association study and meta-analysis of the HTR2C Cys23Ser polymorphism and migraine
    Agustin Oterino
    Service of Neurology, University Hospital Marques de Valdecilla, E 39008, Santander, Spain
    J Headache Pain 8:231-5. 2007
    ..1; 99% CI=0.8-1.5, p=0.499). Our study did not confirm the HTR2C Cys23Ser polymorphism as a risk factor for migraine and MA...
  36. ncbi Correlation between lipophilicity and triptan outcomes
    Julio Pascual
    University Hospital M de Valdecilla, 39008 Santander, Spain
    Headache 45:3-6. 2005
    ..CONCLUSIONS: According to this analysis, a higher lipophilicity does not seem crucial to improve triptan efficacy. This physico-chemical property, however, correlates with higher CNS AE and, possibly, lower recurrence rates...
  37. ncbi Lack of association of endothelial nitric oxide synthase polymorphisms and migraine
    Maria Toriello
    Services of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    Headache 48:1115-9. 2008
    ..The aim of this study was to evaluate if 2 functional endothelial nitric oxide synthase (eNOS) gene polymorphisms might be risk factors for migraine...
  38. ncbi Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability
    Julio Pascual
    University Hospital Neurology, Salamanca, Spain
    Headache 47:1152-68. 2007
    ..In the current literature, there is neither a reported systematic review comparing the efficacy of triptans at 30 minutes and 1 hour after the migraine treatment, nor data related to efficacy of new marketed triptans...
  39. ncbi Bending the rule of monotherapy for migraine prevention?
    Randolph W Evans
    Service of Neurology, University Hospital, Marques de Valdecilla, Santander 39008, Spain
    Headache 45:748-50. 2005
  40. ncbi Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference
    Julio Pascual
    Neurology Service, , Santander, Spain
    Headache 45:1140-50. 2005
    ..The results of this study, using patient-oriented, clinically relevant endpoints such as functional disability and preference, will help to guide practitioners in making recommendations for acute migraine treatment...
  41. ncbi Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain
    Julio Pascual
    , Hospital Valdecilla, Santander, Spain
    Headache 42:93-8. 2002
    ..CONCLUSIONS: Rizatriptan was associated with significantly lower triptan tablet use and additional medication use per attack than the other triptans. Additional randomized studies are needed to confirm the conclusions of this study...
  42. ncbi Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better
    Julio Pascual
    Service of Neurology, , Santander, Spain
    Headache 42:28-31. 2002
    ..When used for mild intensity head pain, almotriptan 12.5 mg produced a significantly higher incidence of pain-free status at 1 and 2 hours and lower incidences of early headache recurrence or need for rescue medication...
  43. ncbi Analysis of endothelial precursor cells in chronic migraine: A case-control study
    Agustin Oterino
    University Hospital Marques de Valdecilla, Spain
    Cephalalgia 33:236-44. 2013
    ..Conclusion: We observed higher number of activated EPCs in migraine patients than in controls. CD62E+ EPCs might be considered a marker for vascular damage in migraine patients...
  44. ncbi Clinical benefits of early triptan therapy for migraine
    Julio Pascual
    Department of Neurology, , Santander, Spain
    Headache 42:10-7. 2002
    ..In sum, early intervention with triptans can improve outcomes, avoiding much of the pain and disability associated with treating moderate or severe attacks...
  45. ncbi Long-term evolution of chronic daily headache with medication overuse in the general population
    Noelia Fontanillas
    Health Center of Santoña, Cantabria, Spain
    Headache 50:981-8. 2010
    ..To investigate long-term efficiency of an intervention protocol for chronic daily headache with medication overuse (CDHwMO) in the general population...
  46. ncbi Almotriptan: an effective and well-tolerated treatment for migraine pain
    Julio Pascual
    University Hospital Marques de Valdecilla, Santander, Spain
    Drugs Today (Barc) 39:31-6. 2003
    ..Almotriptan's high efficacy together with its excellent tolerability and safety profile confirm this new 5-HT(1B/1D) agonist as a drug of choice for the symptomatic treatment of migraine attacks...
  47. ncbi Headaches precipitated by cough, prolonged exercise or sexual activity: a prospective etiological and clinical study
    Julio Pascual
    Service of Neurology, University Hospital of Salamanca, 37007, Salamanca, Spain
    J Headache Pain 9:259-66. 2008
    ....
  48. ncbi [A triptan for every patient?]
    J Pascual Gomez
    Servicio de Neurología Hospital Universitario Marqués de Valdecilla Santander Spain
    Rev Clin Esp 203:545-7. 2003
  49. ncbi Sarcoidosis presenting as transient ischemic attack status
    Isabel González-Aramburu
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    J Stroke Cerebrovasc Dis 21:515-7. 2012
    ..Sarcoidosis should be considered in the differential diagnosis of stroke of unknown origin in any young patient, even in the absence of other clinical or laboratory features of sarcoidosis...
  50. ncbi Fusiform aneurysms of the vertebral artery: a hidden cause of exertional headache?
    Gerard Mauri
    Neuroscience Area, University Hospital Central de Asturias, Oviedo, Spain
    Cephalalgia 32:715-8. 2012
    ..There is only one reported case of recurrent coital headache related to an unruptured saccular aneurysm of the carotid artery...
  51. ncbi What differences exist in the appropriate treatment of congenital versus acquired adult Chiari type I malformation?
    César Ramón
    Neuroscience Area, Service of Neurology, University Hospital Central de Asturias, Calle Celestino Villamil s n, Oviedo 33006, Spain
    Curr Pain Headache Rep 15:157-63. 2011
    ..CSF hypovolemia can be spontaneous or secondary to CSF removal. Treatment of acquired tonsillar herniation depends on the responsible etiology...
  52. ncbi Experience with intravenous levetiracetam in status epilepticus: a retrospective case series
    Gonzalo Gámez-Leyva
    Service of Neurology, University Hospital, Salamanca, Spain
    CNS Drugs 23:983-7. 2009
    ..Status epilepticus is a medical emergency associated with significant morbidity and mortality...
  53. ncbi Topiramate-responsive headache due to idiopathic intracranial hypertension in Behçet syndrome
    Enrique Palacio
    Department of Neurology, University Hospital M de Valdecilla, Santander, Spain
    Headache 44:436-7. 2004
    ..Further studies are necessary, however, to confirm the significance of topiramate in this indication...
  54. ncbi Thymidylate synthase promoter tandem repeat and MTHFD1 R653Q polymorphisms modulate the risk for migraine conferred by the MTHFR T677 allele
    Agustin Oterino
    Services of Neurology, University Hospital Marqués de Valdecilla UC, Santander 39008, Spain
    Brain Res Mol Brain Res 139:163-8. 2005
    ..08; 95% CI = 1.3-7.4). We conclude that the pathogenetic role of the MTHFR T677 allele in migraine is modulated by functional polymorphisms of TS and MTHFD1...
  55. ncbi Primary cough headache, primary exertional headache, and primary headache associated with sexual activity
    Julio Pascual
    Service of Neurology, University Hospital Central de Asturias, Oviedo, Spain
    Handb Clin Neurol 97:459-68. 2010
    ..Cough headache is a different condition when compared to headache due to physical exercise and sexual activity, which are clinical variants of the same entity...
  56. ncbi An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients
    J Pascual
    Services of Neurology, University Hospital, Santander, Spain
    Cephalalgia 21:680-4. 2001
    ..5 mg were equivalent, which suggests that most migraine patients differentiate between triptans. A faster onset of action (speed of onset) was the most important reason for preference...
  57. ncbi Almotriptan: pharmacological differences and clinical results
    J Pascual
    Service of Neurology, University Hospital Marques de Valdecilla, Santander, Spain
    Curr Med Res Opin 17:s63-7. 2001
    ..In summary, almotriptan's promising basic profile together with its excellent tolerability/safety profile and good efficacy confirm this new 5-HT(1B/D) agonist as a drug of choice for the symptomatic treatment of migraine attacks...
  58. ncbi Is Chiari type I malformation a reason for chronic daily headache
    Carmiña Riveira
    Service of Neurology, University Hospital, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
    Curr Pain Headache Rep 11:53-5. 2007
    ..Hydrocephalus and low intracranial pressure syndrome should be ruled out in patients showing tonsillar herniation in an MRI study and consulting due to daily headache...
  59. ncbi Preventing disturbing migraine aura with lamotrigine: an open study
    Julio Pascual
    University Hospital M. de Valdecilla, Neurology, Santander, Cantabria, Spain
    Headache 44:1024-8. 2004
    ..CONCLUSIONS: Lamotrigine should be considered in clinical practice for the preventive treatment of selected patients with disturbing migraine auras. Lamotrigine seems worthy of a controlled trial as prophylaxis of migraine aura...
  60. ncbi Smoking as a precipitating factor for migraine: a survey in medical students
    L López-Mesonero
    Faculty of Medicine, University of Salamanca, Salamanca, Spain
    J Headache Pain 10:101-3. 2009
    ....
  61. ncbi Quality of life in chronic daily headache: a study in a general population
    Victoria Guitera
    Service of Neurology, , Santander, Spain
    Neurology 58:1062-5. 2002
    ..CONCLUSIONS: In the general population, CDH reduced all QoL aspects studied with the SF-36. This reduction in QoL was most marked in subjects with analgesic overuse. QoL was affected more by the chronicity than by the intensity of pain...
  62. ncbi Predictive model for the Migraine-ACT questionnaire in primary care
    Julio Pascual
    Neurology Service, Hospital Universitario de Salamanca, Spain
    Curr Med Res Opin 23:3033-9. 2007
    ..Migraine is frequently under-treated. The 4-item Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire is a simple, patient-friendly tool to identify patients requiring change in acute migraine treatment...
  63. ncbi Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease
    Jon Infante
    Service of Neurology, , Santander, Spain
    Mov Disord 19:848-52. 2004
    ..We conclude that motor neuron symptoms and signs may be a striking manifestation in SCA2, masking pre-existing cerebellar and extrapyramidal semeiology...
  64. ncbi Permanent dysphasia after status epilepticus: long-term follow-up in an elderly patient
    Jose L Fernandez-Torre
    Department of Clinical Neurophysiology, University Hospital Marques de Valdecilla, Santander, Cantabria, Spain
    Epilepsy Behav 8:677-80. 2006
    ..Our case illustrates that permanent language dysfunction may occur after recurrent complex partial and secondarily generalized seizures...
  65. ncbi Tolerability and efficacy of almotriptan in the long-term treatment of migraine
    J Pascual
    Servicio de Neurologia, University Hospital, Santander, Spain
    Eur Neurol 45:206-13. 2001
    ..Purpose: To assess the long-term tolerability and efficacy of oral almotriptan 12.5 mg administered for every migraine attack over a 1-year period...
  66. ncbi Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine
    J Pascual
    , Santander, Spain
    Eur Neurol 45:275-83. 2001
    ..001). Both active treatments were well tolerated. The most common side effects with rizatriptan and sumatriptan were nausea (6.6 and 6.9% of patients, respectively), dizziness (6.1 and 5.8%) and somnolence (7.4 and 6.7%)...
  67. ncbi Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study
    J Pascual
    Servicio de Neurologia, University Hospital, Santander, Spain
    Cephalalgia 20:588-96. 2000
    ..Overall, the 12.5-mg dose was associated with the most favourable efficacy/tolerability ratio and is, therefore, the recommended dose...
  68. ncbi [Determinants of prophylactic migraine therapy in Spain]
    J Pascual Gomez
    Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Espana
    Rev Neurol 45:513-8. 2007
    ..Migraine interferes with the quality of life of patients. Prophylactic medication is an option to be considered in cases showing inefficiency of symptomatic medication or an increase in the number of attacks...
  69. ncbi [Encephalitis due to antibodies against the NMDA receptor. A case report of a female patient with no associated tumour and a literature review]
    Sonia Herrero-Velázquez
    Servicio de Neurologia, Hospital Clinico Universitario de Valladolid, 47005 Valladolid, Espana
    Rev Neurol 50:661-6. 2010
    ..We report on a new case and review the body of knowledge currently available on this recently identified condition...
  70. ncbi Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson's disease: a clinicopathological case study
    Jose Berciano
    Service of Neurology, University Hospital Marques de Valdecilla, University of Cantabria, Santander, Spain
    Mov Disord 17:812-6. 2002
    ..Putaminal preservation accounts for good response to both levodopa therapy and subthalamic nucleus stimulation...
  71. ncbi Epilepsia partialis continua of the abdominal muscles: a detailed electrophysiological study of a case
    Jose L Fernandez-Torre
    Department of Clinical Neurophysiology, Hospital Universitario Marques de Valdecilla, Santander, Spain
    Mov Disord 19:1375-8. 2004
    ....
  72. ncbi Clinical experience with headaches in preadolescent children
    J Pascual
    Department of Medicine and Psychiatry, , Santander, Spain
    Headache 35:551-3. 1995
    ..Even though, in terms of frequency, headache is a very common reason for neurology consultation, the present results show that the majority of preadolescents consulting because of headache suffer from benign conditions...
  73. ncbi Preventive effects of hyperbaric oxygen in cluster headache
    J Pascual
    Service of Neurology, , Santander, Spain
    Headache 35:260-1. 1995
    ..Case 3 only improved in frequency, while the remaining patient showed no benefit. These findings suggest that daily hyperbaric oxygen treatment can be used as a transient preventive treatment for desperate cluster headache sufferers...
  74. ncbi Kaplan Award 1998. Epidemiology of chronic daily headache in the general population
    J Castillo
    Health Center of Camargo, Santander, Spain
    Headache 39:190-6. 1999
    ..The prevalence of chronic daily headache subtypes shown here differs from data obtained from headache clinics, emphasizing that caution is needed in extrapolating data from specialized units to the general population...
  75. ncbi Coexistence of chronic paroxysmal hemicrania and benign cough headache
    I Mateo
    Department of Medicine and Psychiatry, Service of Neurology, , Santander, Spain
    Headache 39:437-8. 1999
    ..The possible pathophysiological significance of this concurrence of both types of indomethacin-responsive pain is discussed...
  76. ncbi [Personality changes in chronic daily headache: a study in the general population]
    V Guitera
    , , , Santander
    Neurologia 16:11-6. 2001
    ..This personality profile is still found more frequently in patients presenting symptomatic medication abuse...
  77. ncbi Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life
    R Colas
    Health Center of Santoña, University Hospital Marqués de Valdecilla UC, Cantabria, Spain
    Neurology 62:1338-42. 2004
    ..To analyze the prevalence and demography of chronic daily headache (CDH) with analgesic overuse...
  78. ncbi Serious migraine: a study of some epidemiological aspects
    J Pascual
    Department of Medicine, , Santander, Spain
    Headache 30:481-4. 1990
    ..Our results may help in planning the public health aspect of migraine and add some light to the natural history of this common condition...
  79. ncbi [New prospects in the treatment of migraine]
    J Pascual
    Servicio de Neurologia, Hospital Universitario Marques de Valdecilla, Santander
    Neurologia 14:26-35. 1999
    ..From this review we conclude that while there have been relevant advances in the symptomatic treatment of migraine, there is a need for the development of better preventive compounds...
  80. ncbi The distinctive headache of the occipital condyle syndrome: a report of four cases
    G Moris
    Department of Medicine and Psychiatry, University Hospital Marques de Valdecilla, Santander, Spain
    Headache 38:308-11. 1998
    ..The occipital condyle syndrome may be the first manifestation of cancer or of chronic inflammatory lesions; recognition of this distinctive headache enables the clinical diagnosis to be made...
  81. ncbi Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients
    E Quintela
    Health Centre of Astillero, University Hospital, Salamanca, Spain
    Cephalalgia 26:1051-60. 2006
    ..In conclusion, around 80% of unselected migraineurs experience RS and PS. Migraine with aura and severe pain are risk factors for experiencing PS and RS, while preventatives were protective, especially for PS...
  82. ncbi GNAS1 T393C polymorphism is associated with migraine
    A Oterino
    Service of Neurology, University Hospital Marqués de Valdecilla UC, Santander, Spain
    Cephalalgia 27:429-34. 2007
    ..20; 95% CI 1.14-4.40; P=0.019) higher than TT/TC genotypes. In conclusion, the GNAS1 T393C variant is associated with migraine, which suggests a genetic basis for its higher SNS sensitivity...
  83. ncbi Good news for chronic migraine
    Julio Pascual
    J Headache Pain 7:169-71. 2006
  84. ncbi More lessons for the treatment of chronic daily headache
    Julio Pascual
    J Headache Pain 9:3-4. 2008
  85. ncbi Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison
    Hans Christoph Diener
    Department of Neurology, University of Essen, Essen, Germany
    Eur Neurol 47:99-107. 2002
    ..001) at 2 h. Adverse events were generally mild or moderate and transient. This randomised trial shows that oral eletriptan is more efficacious in the acute treatment of migraine than oral Cafergot and is well tolerated...
  86. ncbi Everolimus in clinical practice--renal transplantation
    Julio Pascual
    Servicio de Nefrologia, Hospital Ramon y Cajal, Carretera de Colmenar, Km9 100, 28034 Madrid, Spain
    Nephrol Dial Transplant 21:iii18-23. 2006
    ..In conclusion, everolimus may permit reduced exposure to CNIs in renal transplant recipients, with the potential to improve tolerability and renal function...
  87. ncbi How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials
    Carl G H Dahlöf
    Gothenburg Migraine Clinic, Sociala Huset, Sweden
    Headache 42:99-113. 2002
    ..In conclusion, almotriptan's consistent pharmacokinetics and good efficacy, in combination with excellent tolerability, make it an attractive choice in the acute treatment of migraine attacks...
  88. ncbi Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials
    Julio Pascual
    Servicio de Nefrología Hospital, Ramon y Cajal, Carretera de Colemenar km 9, 280034 Madrid, Spain
    Transplantation 78:1548-56. 2004
    ..A new examination of this topic including only randomized, controlled trials based on currently used, new, potent therapy with calcineurin inhibitors and mycophenolate mofetil (MMF), avoiding early trials with azathioprine, is justified...
  89. ncbi Topiramate in the prophylactic treatment of cluster headache
    Miguel J A Láinez
    Department of Neurology, Hospital Clinico Universitario, Universidad de Valencia, Avenida Blasco Ibañez 17, 46 010 Valencia, Spain
    Headache 43:784-9. 2003
    ..The role of topiramate in the prophylactic treatment of cluster headache is still unclear. The aim of this study was to evaluate the effectiveness of topiramate in a group of patients with refractory episodic or chronic cluster headache...
  90. ncbi Cough headache, indomethacin, and surgery
    Julio Pascual
    Headache 44:290. 2004
  91. ncbi Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors
    Julio Pascual
    Servicio de Nefrologia, Hospital Ramon y Cajal, Madrid, Spain
    Transplantation 79:S76-9. 2005
    ..This suggests that concentration-controlled everolimus can be successfully combined with optimized administration of CsA and that this regimen may maximize immunosuppression, whilst preserving renal function...
  92. ncbi Clinical experience with everolimus (Certican): optimizing dose and tolerability
    Julio Pascual
    Servicio de Nefrologia, Hospital Ramon y Cajal, Madrid, Spain
    Transplantation 79:S80-4. 2005
    ..As a result of its mode of action, this class of agent (i.e., everolimus and sirolimus) is associated with certain adverse events (e.g., lymphocele, arthralgia, edema and hyperlipidemia)...
  93. ncbi Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland and Rueil Malmaison, France
    Ther Drug Monit 26:499-505. 2004
    ..Maintaining everolimus troughs in the range 3 to 8 ng/mL in the first posttransplant year with reduced-exposure cyclosporine is associated with good efficacy and safety profiles...
  94. ncbi Clinical experience with everolimus (Certican) in elderly recipients: the "old-for-old" concept
    Julio Pascual
    Servicio de Nefrologia, Hospital Ramon y Cajal, Madrid, Spain
    Transplantation 79:S85-8. 2005
    ....
  95. ncbi Efficacy of therapeutic intervention in headache units in patients with frequent headaches: the EFUNCE study
    Miguel J A Láinez
    Department of Neurology, Hospital Clinico Universitario, University of Valencia, Spain
    Headache 46:818-20. 2006
    ..The results of the first 30 patients showed a significant improvement in different headache parameters and a high degree of satisfaction with the treatment received...
  96. ncbi Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report
    Julio Pascual
    Servicio de Nefrologia, Hospital Ramon y Cajal, Carretera de Colmenar, Km9 100, 28034 Madrid, Spain
    Nephrol Dial Transplant 21:iii38-41. 2006
    ..Therefore, conversion to everolimus from CsA in a renal transplant recipient led to improvements in blood pressure and resolution of recurrent cutaneous neoplasia, with no evidence of rejection or changes in renal function...
  97. ncbi Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant
    Julio Pascual
    Servicio Nefrologia, Hospital Ramon y Cajal, Madrid, Spain
    Transplantation 82:55-61. 2006
    ..The challenge in renal transplantation is to improve long-term patient and graft survival without increasing early acute rejection by minimizing immunosuppression...
  98. ncbi Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial
    Yves Vanrenterghem
    Department of Nephrology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Transplant 5:87-95. 2005
    ..A longer follow-up will be needed to confirm the expected advantages for the long-term outcome and to assess the long-term safety of this minimization of immunosuppressive therapy...
  99. ncbi Ischemic heart disease after renal transplantation in patients on cyclosporine in Spain
    Roberto Marcen
    Department of Nephrology, Ramon y Cajal, Madrid, Spain
    J Am Soc Nephrol 17:S286-90. 2006
    ..Emphasis should be placed on the need to stop smoking and to control hypertension and pre- and posttransplantation levels of serum cholesterol...
  100. ncbi [Chiari type I malformation-related cephalea appearing at the time of blowing during alcohol controls]
    José Carlos Gómez-Sánchez
    Med Clin (Barc) 130:557-8. 2008